Featured Research

from universities, journals, and other organizations

New 'Adjuvant' Could Hold Future Of Vaccine Development

Date:
September 15, 2009
Source:
Oregon State University
Summary:
Scientists have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

Scientists at Oregon State University have developed a new "adjuvant" that could allow the creation of important new vaccines, possibly become a universal vaccine carrier and help medical experts tackle many diseases more effectively.

Related Articles


Adjuvants are substances that are not immunogenic themselves, but increase the immune response when used in combination with a vaccine.

However, due to concerns about safety and toxicity, there's only a single vaccine adjuvant – aluminum hydroxide, or alum – that has been approved for human use in the United States. It's found in such common vaccines as hepatitis B and tetanus. But even though widely used, alum is comparatively weak and will only work with certain diseases.

The new adjuvant is based on nanoparticles prepared with lecithin, a common food product. In animal models, it helped protein antigens to induce an immune response more than six times stronger than when alum was used. Researchers also showed that the lecithin nanoparticles were able to help induce a reasonable antibody response after only one shot, whereas it took at least two shots for the alum adjuvant to work.

Based on their studies, researchers believe the lecithin nanoparticles have wide potential applications and possibly a good safety profile. Their findings were just published in the Journal of Controlled Release, a professional journal in the field of pharmaceutics, in work supported by the National Institute of Allergy and Infectious Diseases.

"In many cases, to make progress with vaccine development we need new adjuvants," said Zhengrong Cui, an assistant professor of pharmaceutics at OSU and corresponding author on the new study. "The material has to be safe, and lecithin is a common food product that's already widely used in pharmaceuticals. This new form of using lecithin nanoparticles as an adjuvant is promising and could become very important."

Vaccine development has always been difficult and at times controversial, Cui said, because of concerns about adverse effects when giving vaccines to healthy people.

Because of that, the U.S. Food and Drug Administration has been conservative about approving new vaccine adjuvants, he said. But even the safety issue is complex – to help avoid risk, new vaccines are based on purified compounds from microbes, but these provoke a very weak immune response and often need an adjuvant to boost them. Vaccines could be made based on dead or live attenuated microbes, but that would have a higher level of risk. The ultimate solution is new and improved adjuvants that help address both concerns about safety and efficacy.

Another problem, he said, is that the alum adjuvant that is common in some U.S. vaccines has very limited value in the development of many potential vaccines against viruses or tumors.

By contrast, the lecithin-based nanoparticle adjuvant is more effective. The extraordinarily small particles move easily to the lymphatic system that plays a key role in development of immune response, and they physically "look like" a pathogen to the immune system, which quickly gears up to fight them.

"Our early studies with laboratory animals seem to suggest that a vaccine based on the lecithin nanoparticle adjuvant would not only be more effective, but be tolerated by the body more readily than one using alum," Cui said. "Lecithin is very non-toxic, it's one of many compounds 'generally recognized as safe' by the FDA, and at the injection site we saw none of the nodules and tissue hardening you sometimes see with vaccines that use alum."

If the new adjuvant is ultimately shown to be safe and is approved following clinical trials, Cui said, it could become the basis for a revolution in the production of vaccines and serve as a universal carrier.


Story Source:

The above story is based on materials provided by Oregon State University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon State University. "New 'Adjuvant' Could Hold Future Of Vaccine Development." ScienceDaily. ScienceDaily, 15 September 2009. <www.sciencedaily.com/releases/2009/09/090914173016.htm>.
Oregon State University. (2009, September 15). New 'Adjuvant' Could Hold Future Of Vaccine Development. ScienceDaily. Retrieved November 1, 2014 from www.sciencedaily.com/releases/2009/09/090914173016.htm
Oregon State University. "New 'Adjuvant' Could Hold Future Of Vaccine Development." ScienceDaily. www.sciencedaily.com/releases/2009/09/090914173016.htm (accessed November 1, 2014).

Share This



More Health & Medicine News

Saturday, November 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins